Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fathi

Showing results (1-10 of 206) with videos related to

Pageof 21
Sort By:
Blood|March 31, 2018
Pevonedistat, a new partner for 5-azacitidineAmir T Fathi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2022
A New Dancing Partner for Venetoclax: GilteritinibAmir T Fathi
The London Hospital Gazette|March 19, 2010
Aspects of arterio-venous and cirsoid aneurysmsJ T FATHI
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2019
Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML PatientAmir T Fathi
The Lancet. Haematology|November 1, 2023
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatmentAmir T Fathi
Blood|November 23, 2013
Emergence of crenolanib for FLT3-mutant AMLAmir T Fathi
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?Yasmin Abaza, Amir T Fathi
Expert Review of Hematology|November 19, 2010
Lestaurtinib: a multi-targeted FLT3 inhibitorAmir T Fathi, Mark Levis
Leukemia & Lymphoma|July 11, 2013
CD30: a new target for ALL?Amir T Fathi, Yi-Bin Chen
Current Opinion in Hematology|January 17, 2018
Induction chemotherapy in acute myeloid leukaemia: origins and emerging directionsVivek A Upadhyay, Amir T Fathi
Pageof 21

Showing results (1-10 of 206) with videos related to

Sort By:
Pageof 21
Blood|March 31, 2018
Pevonedistat, a new partner for 5-azacitidineAmir T Fathi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2022
A New Dancing Partner for Venetoclax: GilteritinibAmir T Fathi
The London Hospital Gazette|March 19, 2010
Aspects of arterio-venous and cirsoid aneurysmsJ T FATHI
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2019
Glasdegib with Low-Dose Cytarabine: A New Upfront Option for the Vulnerable AML PatientAmir T Fathi
The Lancet. Haematology|November 1, 2023
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatmentAmir T Fathi
Blood|November 23, 2013
Emergence of crenolanib for FLT3-mutant AMLAmir T Fathi
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?Yasmin Abaza, Amir T Fathi
Expert Review of Hematology|November 19, 2010
Lestaurtinib: a multi-targeted FLT3 inhibitorAmir T Fathi, Mark Levis
Leukemia & Lymphoma|July 11, 2013
CD30: a new target for ALL?Amir T Fathi, Yi-Bin Chen
Current Opinion in Hematology|January 17, 2018
Induction chemotherapy in acute myeloid leukaemia: origins and emerging directionsVivek A Upadhyay, Amir T Fathi
Pageof 21